Table 2. Risk for all-cause mortality for each 1SD increment in the value of relevant anthropomorphic parameters.

		Men				Women
		non-CKD cohort		CKD cohort		non-CKD cohort		CKD cohort
		HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value
ABSI, +1SD	Model 1	1.38 (1.26 to 1.52)	<0.01	1.23 (1.07 to 1.42)	<0.01	1.09 (1.00 to 1.18)	0.049	1.00 (0.87 to 1.16)	0.97
	Model 2	1.30 (1.18 to 1.43)	<0.01	1.16 (1.01 to 1.34)	0.04	1.07 (0.99 to 1.17)	0.09	0.98 (0.84 to 1.14)	0.78
BMI, +1SD	Model 1	0.90 (0.83 to 0.97)	<0.01	0.87 (0.78 to 0.98)	0.02	0.97 (0.89 to 1.06)	0.53	1.15 (1.02 to 1.31)	0.03
	Model 2	0.87 (0.80 to 0.94)	<0.01	0.84 (0.74 to 0.95)	0.01	0.91 (0.83 to 1.00)	0.047	1.03 (0.90 to 1.19)	0.66
WC, +1SD	Model 1	1.02 (0.94 to 1.10)	0.64	0.93 (0.83 to 1.05)	0.22	1.01 (0.93 to 1.11)	0.75	1.13 (0.98 to 1.29)	0.09
	Model 2	0.98 (0.90 to 1.06)	0.59	0.88 (0.78 to 1.00)	0.045	0.96 (0.88 to 1.05)	0.38	1.00 (0.86 to 1.16)	0.99
WHtR, +1SD	Model 1	1.02 (0.94 to 1.11)	0.59	0.98 (0.86 to 1.10)	0.70	1.03 (0.95 to 1.12)	0.43	1.15 (1.01 to 1.31)	0.04
	Model 2	0.98 (0.90 to 1.07)	0.59	0.93 (0.82 to 1.06)	0.27	0.98 (0.90 to 1.07)	0.67	1.03 (0.90 to 1.19)	0.67

Risk was assessed using Cox regression analysis. Model 1 was adjusted for age and sex. Model 2 consisted of Model 1 + adjustments for systolic blood pressure (+1SD), high-density lipoprotein cholesterol (+1SD), glycated hemoglobin (+1SD), estimated glomerular filtration rate (+1SD), drug use (anti-hypertension, anti-diabetes, or anti-dyslipidemia), past history of cardiovascular disease, and current smoking status (smoker).

Data given as hazard ratio (HR) with 95% confidence interval (95%CI).

Abbreviations: ABSI, a body shape index; BMI, body mass index; CKD, chronic kidney disease; SD, standard deviation; WC, waist circumference; WHtR, waist-to-height ratio.